Prevalence of homebound 22 percent in national Medicare Advantage plan
Aug 12, 2024
Homebound status linked to increased odds of ED visit, inpatient admission, skilled nursing-facility admission, mortality
New deals will cut Medicare costs for expensive drugs
Aug 15, 2024
The Biden administration said Thursday that it has signed deals with drug companies that will lower the prices on 10 of the most popular and expensive drugs used by American seniors.
Women undergoing CABG more likely to get care at low-quality hospitals
Jul 29, 2024
More than fourfold higher mortality was seen for women Medicare beneficiaries receiving coronary artery bypass grafting at low-quality hospitals than male beneficiaries at high-quality hospitals.
Disparities in post-acute stroke care depend on insurance status
Jul 17, 2024
Uninsured patients had the lowest odds of facility versus home discharge and home healthcare discharge versus home without home healthcare.
Medicare could have saved $3.6 billion on generic drugs in 2020
Jun 20, 2022
The authors say that Medicare could have saved up to $3.6 billion by purchasing generics at Mark Cuban Cost Plus Drug Co. prices.
Private equity acquisition of hospitals may increase adverse events
Dec 26, 2023
Medicare beneficiaries admitted to private equity hospitals experienced increase in hospital-acquired conditions
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Rural, urban disparities seen for quality of home healthcare
Jan 13, 2022
Rural home health care agencies perform better on process measures; urban agencies perform better on outcome measures.
Heart, diabetes, cancer drugs on list for Medicare price negotiations, White House says
Aug 29, 2023
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636